Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Liabilities and Shareholders Equity (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $3.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 10.06% to $3.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $23.7 million, a 6.76% increase, with the full-year FY2024 number at $3.4 million, down 62.11% from a year prior.
  • Liabilities and Shareholders Equity was $3.5 million for Q3 2025 at NovaBay Pharmaceuticals, down from $6.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $24.8 million in Q1 2022 to a low of $3.4 million in Q4 2024.
  • A 5-year average of $12.6 million and a median of $12.9 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: plummeted 75.48% in 2024, then soared 84.28% in 2025.
  • NovaBay Pharmaceuticals' Liabilities and Shareholders Equity stood at $24.0 million in 2021, then crashed by 31.61% to $16.4 million in 2022, then crashed by 44.91% to $9.0 million in 2023, then tumbled by 62.11% to $3.4 million in 2024, then grew by 1.87% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Liabilities and Shareholders Equity are $3.5 million (Q3 2025), $6.9 million (Q2 2025), and $9.9 million (Q1 2025).